Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
100 results about "Treatment refractory" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Refractory is a term used to describe something that is difficult to treat or cure. H. pylori infection can be refractory to treatment for a number of reasons. The refractoriness may not be real. Successfully cured patients are sometimes referred to specialists because of positive serology tests.
Antibody drug conjugate metabolites
ActiveUS7750116B1Improve drug bioavailabilityImprove bioavailabilityPeptide/protein ingredientsImmunoglobulinsMetaboliteWilms' tumor
Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites.
Owner:SEAGEN INC
Peripheral Nerve Stimulation
Owner:WEINER RICHARD L
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.
Owner:JANSSEN PHARMA NV
Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters
InactiveUS20120258994A1Improve the level ofIncrease ratingsBiocideNervous disorderMetaboliteMedicine
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and / or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals.
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00001.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00002.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
![Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters](https://images-eureka.patsnap.com/patent_img/2b76e59b-93e8-4227-9e24-297ff8ce8302/US20120258994A1-20121011-D00003.png "Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters")
Owner:ETHISMOS RES INC
Methods of treating drug-resistant cancers
ActiveUS20100260786A1Improve drug bioavailabilityImprove bioavailabilityPeptidesAntibody ingredientsRefractoryOncology
Owner:SEAGEN INC
Methods for the treatment of il-1beta related conditions
ActiveUS20120014966A1Reduce frequencyReduce the possibilityAntibacterial agentsSenses disorderUveitisAntigen binding
Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof).
Owner:XOMA US
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Owner:JANSSEN PHARMA NV
Treatment of refractory cancers using Na+/K+-ATPase inhibitors
InactiveUS20080027010A1Improve stress responseGood tumor growthBiocideOrganic active ingredientsATPaseAglycone
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.
Owner:BIONAUT PHARMA
Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease
Owner:NOGRA PHARMA LTD
VHL peptide
InactiveUS20060270834A1Improve permeabilityPeptide/protein ingredientsPeptide sourcesHuntingtons choreaBrain Contusion
Intractable neuronal diseases are treated by inducing differentiation of neural stem cells into neurons without accompanying a risk such as cytotoxicity and infection. Intractable neuronal diseases, such as Parkinson's disease, cerebral infarction, Alzheimer's disease, spinal cord injury, brain contusion, amyotropic lateral sclerosis, Huntington's disease, malignant tumor, and the like, are treated by regeneration therapy by transferring VHL peptides which can induce differentiation of neural stem cell into neurons into neural stem cells to induce differentiation of neural stem cells into neurons or by administering VHL peptides directly into a human body to induce differentiation of endogeneous stem cells into neurons.
Owner:HIROSHI KANNO +1
Neuronal differentiation method of adult stem cells using small molecules
The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury.
Owner:KOREA RES INST OF CHEM TECH
Agent for reduction of scar formation by using wound alkalinization
InactiveUS20030180390A1Efficient use ofReduce scarsBiocideInorganic active ingredientsSodium bicarbonateDisease
The present invention relates to an agent for reducing scar formation, which inhibits the scar formation by injecting sodium bicarbonate to the dermis tissue of the wound with a syringe to directly control pH of the wound site, namely, by alkalinizing the wound to inactivate TGF-beta. According to the present invention, the agent for reducing scar formation by controlling the wound healing process can be clinically and immediately applied to the treatment of tylosis scar and keloid, etc., and is effective to the treatment of intractable fibrosis diseases. Also, the invention can be widely applied in many ways as an easy tool which can control the action of TGF-beta in a living organism.
Owner:OSIRIS THERAPEUTICS
Method for prevention or treatment of intractable inflammatory bowel disease
ActiveUS20130296260A1Peptide/protein ingredientsAntipyreticInflammatory bowel diseaseSteroid dependency
An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
Owner:UNIVERSITY OF MIYAZAKI
Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate
The invention provides a pharmaceutical composition containing sodium hyaluronate with the relatively medium molecular weight and chondroitin sulfate with the relatively low molecular weight. The molecular weight of sodium hyaluronate is 200 kD-1,000 kD, the concentration of sodium hyaluronate is 1%-2%, the molecular weight of chondroitin sulfate is 5 kD-10 kD, and the concentration of chondroitin sulfate is 1.5%-3%. The pharmaceutical composition contains chondroitin sulfate with the relatively low molecular weight, has the better treatment effect than single sodium hyaluronate and can be used for treating refractory nonbacterial cystitis, Chronic recurrent bacterial cystitis, radiation-induced cystitis, interstitial cystitis (the chronic bladder pain syndrome) and neurogenic bladder urinary system infection.
Owner:成都金思唯生物技术有限公司
Treatment of refractory neuropsychiatric disorders using targeted radiation
Provided herein are methods for treating neuropsychiatric disorders by delivering radiation to an area in the subgenual anterior cingulate cortex, particularly to the cingulate area 25. Those methods are also beneficial to treat refractory neuropsychiatric disorders.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Multipotent adult stem cells having an ability of oct4 expression derived from umbilical cord blood and method for preparing the same
InactiveUS20090305413A1Negative immunological responseBlood/immune system cellsCell culture active agentsGerm layerDisease
The present invention relates to multipotent adult stem cells expressing Oct4, derived from umbilical cord blood (UCB) and also these cell are expressing CD29, CD31, CD44, simultaneously, a method for preparing the same, and more specifically to multipotent adult stem cells which are obtained by culturing umbilical cord blood-derived monocytes in a medium containing bFGF (basic fibroblast growth factor) and human serum or plasma. In addition, multipotent adult stem cells expressing Oct-4 from UCB are morphologically spindle or round shaped cells Although the stem cells according to the present invention are adult stem cells, they are multipotent and capable of differentiating into ectodermal-, messodermal-, endodermal-originated tissue or cells including osteogenic cells or nerve cells etc, thus they can be effectively used in the treatment of intractable diseases and incurable diseases.
Owner:SEOUL NAT UNIV R&DB FOUND
Ketogenic mix preparation suitable for treating intractable epilepsy
InactiveCN101269210APromote brain developmentPromote fat metabolismNervous disorderPeptide/protein ingredientsAdditive ingredientMedicine
The invention relate to a ketogenesis mixture preparation applicable for treating refractory epilepsy, which is characterized in that: (1) fat, protein and carbohydrate form the basic prescription, a small amount of essential vitamins, minerals and aminophenol promoting the growth and the development of the human body and brain and promoting the metabolism are added in the basic prescription; (2) in the basic preparation, the weight percentages of the components are respectively that: fat 70-80 percent, protein 15-20 percent, carbohydrate 5-10 percent; (3) the physical states of all the components in the basic preparation are powder, ointment, aqua, or solid state agent. The physical states of the ketogenesis mixture preparation are powder granule, electuary, liquid agent, tablet, capsule or other solid state agent. The ketogenesis mixture preparation aims at the special nutrition requirement of Chinese, nutritional ingredient promoting the development of the brain and the metabolism is added in, the curative efficiency on refractory epilepsy reaches 80 percent, which reaches or exceeds the curative effect of the equivalent product abroad.
Owner:邓荣光
Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
InactiveUS20070197538A1Good conditionImprove treatmentBiocideAnimal repellantsDiseaseProtein-Tyrosine Kinases
This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders / conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.
Owner:AVENTIS PHARMA SA (US)
Kit and method for detecting genes related to individualized medication for depression
PendingCN110157793APredict efficacyPredictive reactivityMicrobiological testing/measurementDNA/RNA fragmentationDrug metabolismNucleotide
The invention discloses a primer group, a kit and a detection method for detecting genes related to individualized medication for depression. The primer group is selected from nucleotide sequences inSEQ ID NO.1-SEQ ID NO.154. The detection kit covers eight major categories of clinical first-line and second-line antidepressant efficacy-related genes, and relates to drug metabolism, target spots and transporter gene loci, and detection is conducted comprehensively and accurately. Accordingly, aiming at part of patients suffering from treatment-refractory depression, gene detection related to the therapeutic effect of antidepressant synergistic drugs is added, and powerful support is provided for selection of therapeutic schedules of the treatment-refractory depression.
Owner:广州海思医疗科技有限公司
Method for treating a refractory or relapsed lung cancer
ActiveUS20170080048A1Peptide/protein ingredientsPharmaceutical delivery mechanismOncologyLung cancer
The present invention relates to a method for treating a refractory or relapsed lung cancer. Particularly, the invention provides a method and a formulation of using an immunomodulatory protein derived from Ganoderma microsporum in the treatment of a refractory or relapsed lung cancer.
Owner:MYCOMAGIC BIOTECH
Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
InactiveUS20140039029A1Improve the level ofIncrease ratingsBiocideNervous disorderMetaboliteMedicine
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00001.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00002.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
![Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters](https://images-eureka.patsnap.com/patent_img/86e54128-cac6-436d-9880-fa6475ebd150/US20140039029A1-20140206-D00003.png "Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters")
Owner:ETHISMOS RES INC
Compound medicine preparation for treating refractory hypertension
InactiveCN107308181AAvoid careful counting of multiple drug quantitiesAvoid the hassle of dosingOrganic active ingredientsCardiovascular disorderCaptoprilSide effect
The invention discloses a compound medicine preparation for treating refractory hypertension, which is mainly prepared from the following components in parts by weight: 50 to 500 parts of ganoderan, 5 to 10 parts of nifedipine, 12.5 to 50 parts of captopril, 10 to 50 parts of hydrochlorothiazide and 12.5 to 100 parts of atenolol. According to the compound medicine preparation provided by the invention, the ganoderan is compounded with multiple antihypertensive drugs of conventional multiple-treatment to prepare a convenient-to-take compound preparation; the beneficial effects of synergetic antihypertensive effect and mutual side effect relieving / offsetting effect of the ganoderan and the four medicines are realized, the compliance of standardized medicine-taking of refractory hypertension patients is obviously improved, the therapeutic effect of obviously reducing the blood pressure level of the refractory hypertension or even realizing up-to-standard blood pressure control on part of the patients are achieved, and a novel convenient-to-take compound antihypertensive drug is provided for simplifying the drug use of the refractory hypertension patients and effectively reducing the blood pressure level.
Owner:卢广荣
Deuterated dehydrophenylahistin compounds and preparation method thereof and use thereof in preparation of Anti-tumor drugs
ActiveUS20180140600A1High deuterateOrganic active ingredientsIsotope introduction to heterocyclic compoundsDepolymerizationBenzaldehyde
Provided are a deuterium-substituted dehydrophenylahistin-like compound, preparation method thereof and use in a preparation of antitumor drugs. The deuterium-substituted dehydrophenylahistin-like compound has a structure of general formula (I), and a synthesis method thereof comprises: firstly conducting a condensation reaction of diacetyldiketopiperazine and an aldehyde intermediate a or a deuterated aldehyde compound b to form a heterocyclic compound c or a deuterium-containing heterocyclic compound d, which is then subjected to a condensation reaction with benzaldehyde and a deuterium-substituted benzaldehyde-like compound to form the deuterium-substituted dehydrophenylahistin-like compound. Also provided are a highly effective deuterated aldehyde intermediate with a high deuterium substitution rate and a deuterium-containing heterocycle intermediate, and a synthesis method thereof. An experiment shows that the deuterium-substituted dehyd-rophenylahistin-like compound provided by the present invention has an effect on tubulin depolymerization and can treat a refractory solid tumor or lymphoma. The present invention provides a method for researching and developing antitumor drugs of the related compound.
Owner:SHENZHEN HUAHONG MARINE BIOMEDICINE CO LTD
Biological gel for treating refractory skin damage and application of biological gel
ActiveCN107488627AWith strengthStable living environmentMetabolism disorderAerosol deliverySide effectIrritation
The invention relates to biological gel for treating refractory skin damage and application of the biological gel. The biological gel is prepared from umbilical cord mesenchymal stem cells coated by biocompatible degradable gel with special stem cell culture additives, wherein the stem cell culture additives comprise umbilical cord mesenchymal stem cells, traditional Chinese medicine extracts and serum. The biological gel provided by the invention is capable of promoting normal body cell proliferation, reducing influence of common negative irritation such as anoxia and chemotherapy to normal body cells, prolonging cell growth time, promoting cell factor secretion and effectively treating refractory skin damage such as burning and scalding, and is safe and efficient, small in side effect, simple to product and low in cost.
Owner:上海亚睿生物科技有限公司
Application of SB202190 in preparation of medicines for treating intractable epilepsy
InactiveCN104606192AIncreased drug resistanceIncrease useOrganic active ingredientsNervous disorderAntiepileptic drugMultidrug transporter
The invention relates to application of SB202190 in preparation of medicines for treating intractable epilepsy. By utilizing an intractable epilepsy animal model, due to a series of researches, the SB202190 can reduce the expression of multidrug transporter-P glycoprotein (PGP) related to drug tolerance in the brain of an intractable epilepsy rat, the drug concentration of antiepileptic drugs (AEDs) in hippocampus cell extracellular fluid of the intractable epilepsy rat is improved, the AEDs is assisted to improve the electrophysiological activity of the rat, and the ignition post-attack classification is reduced, namely the drug tolerance of the intractable epilepsy can be improved by the SB202190. The application of the SB202190 is widened, and an effective way is provided for treatment of the intractable epilepsy.
Owner:JINSHAN HOSPITAL FUDAN UNIV
Deuterated dehydrophenylahistin compounds and preparation method thereof and use thereof in preparation of anti-tumor drugs
ActiveUS10434098B2High deuterateOrganic active ingredientsIsotope introduction to heterocyclic compoundsDepolymerizationSynthesis methods
Owner:SHENZHEN HUAHONG MARINE BIOMEDICINE CO LTD
Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof
ActiveCN104906554AAvoid acid suppressant therapyThe total clinical effective rate is highDigestive systemPlant ingredientsClinical efficacyCoptis
The invention relates to a traditional Chinese medicine composition for treating the refractory gastroesophageal reflux disease. The composition is produced through medicinal materials of inula stems, mangnolia officinalis, coptis, fructus evodiae, ginger, calcined flute, Chinese thorowax roots, corydalis tuber, rhizoma cyperi, stir-baked fructus gardenia, bitter orange, sealwort, radix paeoniae alba and liquorice. The invention further provides an application of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the application have the advantages that the composition is used for treating the refractory gastroesophageal reflux disease, symptoms of substernal pains and discomfort, throat discomfort, heartburn, sour regurgitation, belching and the like are improved apparently, and the clinical efficacy rate is high.
Owner:YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE
Quinonemethide triterpenoids and pharmaceutical compositions for the treatment of refractory rheumatoid arthritis
ActiveCN109223804AConvenient treatmentFavorable targetingOrganic active ingredientsAntipyreticFibroblast like synovialHomeostasis
Application of a quinonemethide triterpenoid or a pharmaceutically tolerable salt, solvate or anhydrate thereof in preparing medicine for the treatment of refractory rheumatoid arthritis, and application in medicine for inducing autophagy in a synovial fibroblast. Further a pharmaceutical composition includes an effective dose of a quinonemethide triterpenoid and an anti-arthritis compound. The quinonemethide triterpenoid is suitable to treat refractory rheumatoid arthritis (RA), in particular ABC-protein-dependent RA and apoptosis-deficient RA. The quinonemethide triterpenoid also possesses significant inhibitory effects on the growth of synovial fibroblasts, in particular modulating the calcium homeostasis in multidrug-resistant rheumatoid arthritis synovial fibroblasts.
Owner:MACAU UNIV OF SCI & TECH
Inos-inhibitory compositions and their use as breast cancer therapeutics
InactiveUS20170020835A1Unexpected benefitEasy to useInorganic active ingredientsAntibody ingredientsRefractoryHuman breast
Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.
Owner:THE METHODIST HOSPITAL
Treatment of multiple myeloma with masitinib
InactiveUS20140051662A1Effective treatmentSimple methodBiocideBoron compound active ingredientsTargeted therapyCancer research
The present invention relates to the treatment of multiple myeloma, especially for the treatment of those patients with refractory or first relapsed multiple myeloma, and in particular patients with t(4;14) multiple myeloma, comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt thereof, administered in association with an additional care in multiple myeloma; for example, autologous stem-cell transplantation, targeted therapies, anti-myeloma agents such as alkylating agents, corticosteroids, or immunomodulatory agents, including bortezomib, lenalidomide, and dexamethasone.
Owner:AB SCIENCE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com